Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Debora Carpanese"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Triple-negative breast cancer (TNBC) represents a major therapeutic challenge due to its heterogeneous and aggressive phenotype, and limited target-specific treatment options. The trophoblast cell surface antigen (Trop-2), a transmembrane glycoprotei
Externí odkaz:
https://doaj.org/article/adca9cc092b84af8a17406c74153307d
Autor:
Cristina Bolzati, Carolina Gobbi, Guillermina Ferro-Flores, Sofia Turato, Blanca Ocampo-Garcia, Debora Carpanese, Cristina Marzano, Barbara Spolaore, Giulio Fracasso, Antonio Rosato, Laura Meléndez-Alafort
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 1, p 492 (2023)
Previously, we demonstrated that the 177Lu-labeled single-chain variable fragment of an anti-prostate-specific membrane antigen (PSMA) IgG D2B antibody (scFvD2B) showed higher prostate cancer (PCa) cell uptake and tumor radiation doses compared to 17
Externí odkaz:
https://doaj.org/article/bb6461fa297a46f4943826c05c663bb6
Autor:
Nicoletta Rigamonti, Jessica Sebellin, Francesca Pipitone, Nicola Realdon, Debora Carpanese, Marina Coppola
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1429 (2023)
Background. Preparation of injectable anticancer drugs in hospital pharmacies is a high-risk activity that requires a proper risk assessment (RA) and quality assurance system (QAS) to ensure both a decrease in risk associated with chemotherapy compou
Externí odkaz:
https://doaj.org/article/d3a0573a6b7a4abbae45bb810550d1f1
Autor:
Debora Carpanese, Guillermina Ferro-Flores, Blanca Ocampo-Garcia, Clara Santos-Cuevas, Nicola Salvarese, Mariangela Figini, Giulio Fracasso, Laura De Nardo, Cristina Bolzati, Antonio Rosato, Laura Meléndez-Alafort
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Abstract The clinical translation of theranostic 177Lu-radiopharmaceuticals based on inhibitors of the prostate-specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with advanced prostate cancer (PCa). However, ch
Externí odkaz:
https://doaj.org/article/9b2d1ad6b66740dab5e3f6564255938b
Autor:
Gaia Zuccolotto, Alessandro Penna, Giulio Fracasso, Debora Carpanese, Isabella Monia Montagner, Silvia Dalla Santa, Antonio Rosato
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Prostate cancer (PCa) is the second leading cause of malignancy-related mortality in males in the Western world. Although treatment like prostatectomy and radiotherapy for localized cancer have good results, similar positive outcomes are not achieved
Externí odkaz:
https://doaj.org/article/984e176b88974b16bfb1e2cd515d63f3
Autor:
Nicola Salvarese, Debora Carpanese, Laura Meléndez-Alafort, Laura De Nardo, Andrea Calderan, Barbara Biondi, Paolo Ruzza, Antonio Rosato, Cristina Bolzati
Publikováno v:
Molecules, Vol 27, Iss 8, p 2548 (2022)
Background: The [99mTc][Tc(N)(PNP)] system, where PNP is a bisphosphinoamine, is an interesting platform for the development of tumor ‘receptor-specific’ agents. Here, we compared the reactivity and impact of three [Tc(N)(PNP)] frameworks on the
Externí odkaz:
https://doaj.org/article/624b5dfef7824c07b6bc0cf22645f34f
Autor:
Sara Brunello, Nicola Salvarese, Debora Carpanese, Carolina Gobbi, Laura Melendez-Alafort, Cristina Bolzati
Publikováno v:
Molecules, Vol 27, Iss 9, p 2617 (2022)
Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor nuclear molecular imaging as an excellent target for both the diagnosis and therapy of prostate cancer. Since 2008, after years of preclinical research efforts, a plenti
Externí odkaz:
https://doaj.org/article/f336efa2ba0042f4a15569a5cc37cbba
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells
Autor:
Roberta Sommaggio, Elisa Cappuzzello, Anna Dalla Pietà, Anna Tosi, Pierangela Palmerini, Debora Carpanese, Lorenzo Nicolè, Antonio Rosato
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Cytokine-Induced Killer (CIK) cells share several functional and phenotypical properties of both T and natural killer (NK) cells. They represent an attractive approach for cell-based immunotherapy, as they do not require antigen-specific priming for
Externí odkaz:
https://doaj.org/article/eebe901439664a3eb3794810f138b09f
Autor:
Isabella Monia Montagner, Alessandro Penna, Giulio Fracasso, Debora Carpanese, Anna Dalla Pietà, Vito Barbieri, Gaia Zuccolotto, Antonio Rosato
Publikováno v:
Cells, Vol 9, Iss 6, p 1382 (2020)
Prostate cancer (PCa) has become the most common cancer among males in Europe and the USA. Adoptive immunotherapy appears a promising strategy to control the advanced stages of the disease by specifically targeting the tumor, in particular through ch
Externí odkaz:
https://doaj.org/article/25cc19c2c9d440d09da59b005566c588
Autor:
Lisa Faoro, Adriana Brusegan, Alberto Russi, Vincenzo Calderone, Alma Martelli, Ettore Marranconi, Debora Carpanese, Elena Berti, Marina Coppola
Publikováno v:
BMC Pharmacology and Toxicology. 24
Background Many trials supported pembrolizumab as a first-line monotherapy to significantly improve overall survival (OS) in selected patients with previously untreated metastatic Non–Small Cell Lung Cancer (mNSCLC) and a PD-L1 TPS of ≥50% withou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e918a3fd53ae8f3d062e15406bd1f65
https://doi.org/10.1186/s40360-023-00663-0
https://doi.org/10.1186/s40360-023-00663-0